Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Novavax's (NVAX) JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md., June 24, 2024 /PRNewswire/ -- Novavax, Inc., a global company advancing ...

(RTTNews) - Biotechnology company Novavax, Inc. (NVAX) announced Monday that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its ...

Weeks after the Centers for Disease Control and Prevention signed off on Novavax’s two-dose COVID vaccine, the biotechnology company is seeking approval to distribute booster shots. Novavax announced ...

Novavax spent much of 2021 working to file its COVID-19 vaccine with U.S. regulators but falling short of its own deadlines. As the year came to a close, the company celebrated the fact that it was ...

-- Takeda submits application for TAK-019/NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for NDA, to Japan's Ministry of Health, Labour and Welfare (MHLW) -- Interim data from Phase 1 ...

Novavax's (NVAX) updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available ...

GAITHERSBURG, Md., June 14, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an ...

"Novavax is working closely with European markets seeking to offer a protein-based alternative to mRNA this fall for COVID-19 vaccination," said John C. Jacobs, President and Chief Executive Officer, ...